Abstracts

SASMO Submission
SASCeTS Submission

Abstracts submissions open:
16 February 2026

Abstract submissions extended to:
17 June 2026

Notifications to submitters:
13 July 2026

SASMO Categories

  1. Radiation Oncology
  2. Medical Oncology
  3. Paediatric Oncology
  4. Gynaecologic Oncology
  5. Radiation Therapy
  6. Psychosocial, Nurses and AHP’s

SASCeTS Categories

  1. Stem cell transplantation – Clinical
  2. Stem cell transplantation – Laboratory
  3. Stem cell transplantation – Basic Science
  4. Clinical Haematology – Clinical
  5. Clinical Haematology – Laboratory
  6. Clinical Haematology – Basic Science
  7. Allied Healthcare Professionals Presentation
  8. Presentation by an NPO

Abstract Structure & Formatting

Original Research Abstracts

Original research abstracts should preferably not have been previously accepted for publication or presented at another conference.

Abstracts must be structured as follows:

  • Introduction
    Brief background to the research topic, clearly identifying the problem and the aim of the study.
  • Methodology
    A concise description of the study design, methods, and techniques used.
  • Results
    Clear and specific presentation of results obtained. Abstracts stating “results will be presented” or “will be discussed” will not be accepted.
  • Discussion and Conclusions
    Interpretation of findings, significance of results, and implications for clinical practice or future research.

 

Word Limits

  • Title: Maximum 50 words
  • Abstract body: Maximum 350 words

Review and Selection

Abstract Review

All submitted abstracts will be reviewed by the SASMO-SASCeTS Programme Committee. Abstracts will be evaluated based on scientific merit, relevance to the conference themes, clarity, and originality.

Notification of acceptance or rejection

  • All submitting authors will be informed in writing of the outcome of their abstract submission.
  • Only the submitting author will receive official correspondence and is responsible for informing co-authors.

Abstract withdrawal

An abstract may be withdrawn upon written request by the submitting author.

  • Requests must include the submitting author’s name and abstract title.
  • Withdrawal requests should be sent to: chantell@soafrica.com

Adcock Ingram is a Proudly South African company. Adcock Ingram manufactures, markets, sells and distributes a wide range of products. The diversified portfolio includes an extensive portfolio of branded and generic prescription medicines.

www.adcock.com

Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Ukraine and Eurasian countries, and Latin America.

We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing.

https://acino.swiss/

M-ZA-00002893 Expiration Date 07/03/2027

Roche Pharmaceuticals: Leading the Charge in Oncology

Roche is one of the world’s largest biotechnology company and has spent over 125 years redefining cancer care through a fusion of innovative therapies and precision medicine1.In Africa, Roche is one of the primary drivers of oncology advancements, leveraging a vast clinical trial network to deliver targeted treatments for HER2-positive breast cancer and now incorporating the lung cancer2.


Central to its regional mission is the Africa Breast Cancer Ambition, a bold initiative to rewrite the continent's survival narrative. Currently, only 5 in 10 African women survive breast cancer; Roche aims to increase this to 8 in 103 by 20404. To achieve this, Roche is committed to three critical pillars:

  • Early Detection: Increasing stage I/II diagnoses from 30% to 60%.5
  • Faster Diagnosis: Reducing the journey from symptoms to treatment to just 60 days.6
  • Treatment Access: Ensuring 80% of patients receive the standard of care.7

Through these interventions, Roche is dedicated to doing now what patients need next, pioneering an innovative pipeline to improve clinical outcomes and extend the lives of patients in South Africa.

https://www.roche.co.za/about


Roche Products (Pty) Ltd, P O Box 1469, Halfway House, 1685. Tel. +27-11-504-4746 Registration No. 1947/027044/07 Building E, Hertford Office Park, 90 Bekker Road, Vorna Valley, Midrand, 1686 Directors: R. Ferraro (Chairman) (Swiss) Dr S.D. Diale T.G. (South Africa) Renwick (British)

1 Roche South Africa. About Roche [Internet; updated 2026 Feb; cited 2026 Mar 2]. Available from: About Roche ZA

2 Roche. A new era of healthcare in Africa with AMA [Internet; updated 2026 Feb; cited 2026 Mar 2]. Available from: A new era of healthcare in Africa with AMA

3 Roche. African Breast Cancer Ambition (ABCA) [Internet; cited 2026 Mar 2]. Available from: Africa Breast Cancer Ambition

4 Africa Breast Cancer Council. Our Objectives [Internet; updated 2026; cited 2026 Mar 2]. Available from: Africa Breast Cancer Council Objectives

5 Africa Breast Cancer Council. Our Objectives [Internet; updated 2026; cited 2026 Mar 2]. Available from: Africa Breast Cancer Council Objectives

6 Africa Breast Cancer Council. Our Objectives [Internet; updated 2026; cited 2026 Mar 2]. Available from: Africa Breast Cancer Council Objectives

7 Roche Africa. Working together to help more women in Africa survive breast cancer [Internet; updated 2026 Feb; cited 2026 Mar 2]. Available from: Working together to help more women in Africa survive breast cancer